Podcast
MSL Talk: Tom Caravela, Linda Traylor, Rena Patel
Why and How to Build a “Community” MSL Team
Summary
In this episode, Bobby Faison joins to discuss the concept and implementation of community MSL teams. The conversation highlights the importance of building these teams, their roles in KOL mapping, and effective engagement strategies. Bobby covers essential aspects such as hiring, qualifications, and entry-level opportunities for community MSLs, alongside the challenges they face. The episode delves into the dynamics between community MSLs and commercial teams, territory management, and travel considerations. Bobby also examines the metrics for assessing the community MSL model's success and offers career advancement advice. The episode concludes with insights into customer segmentation and its impact on field medical teams.
My guest today is Bobby Faison, Executive Director, Medical Affairs with Paratek Pharmaceuticals. Bobby discusses why and how to build a “Community” MSL team.
Bobby shares…
👉 What is a “Community” MSL
👉 How a “Community” MSL is different from a traditional, therapeutic MSL
👉 What the relationship with commercial looks like
👉 What the expectations are for “Community” MSLs in regard to metrics and KPIs
👉 Advice for organizations looking to implement this model
👉 Why the Community MSL role is a great pathway for Aspiring MSLs
Community MSL teams, KOL mapping, community MSL roles, engagement strategies, MSL career advancement
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Linda Traylor, Rena Patel
Podcast
MSL Talk: Tom Caravela, Omar McMillan
Digital Opinion Leaders: What You Should Know About DOLs
Article
Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
Article
Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Article
Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
Article
iNIZIO